New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack

The company is now mulling over its future, which might include sale of the business, restructure, or dissolving […]

Rinvoq is a selective and reversible JAK inhibitor being studied in several immune-mediated inflammatory diseases

Updated Date: Tue, 26 May 2020 00:00:00 EDT

Updated Date: Tue, 26 May 2020 00:00:00 EDT

Updated Date: Tue, 26 May 2020 00:00:00 EDT

Updated Date: Tue, 26 May 2020 00:00:00 EDT

Updated Date: Tue, 26 May 2020 00:00:00 EDT

Emergent BioSolutions, BARDA reach $628M deal to manufacture COVID-19 vaccine hopefuls kblankenship Mon, 06/01/2020 – 15:33

WuXi AppTec welcomes vet of Celgene’s troubled cell therapy program to CAR-T leadership role kblankenship Mon, 06/01/2020 – […]